Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.
Vaccine strategies aimed at blocking virus entry have so far failed to induce protection against heterologous viruses. Thus, the control of viral infection and the block of disease onset may represent a more achievable goal of human immunodeficiency virus (HIV) vaccine strategies. Here we show that vaccination of cynomolgus monkeys with a biologically active HIV-1 Tat protein is safe, elicits a broad (humoral and cellular) specific immune response and reduces infection with the highly pathogenic simian-human immunodeficiency virus (SHIV)-89.6P to undetectable levels, preventing the CD4+ T-cell decrease. These results may provide new opportunities for the development of a vaccine against AIDS.
Cafaro
A
A
Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.
Caputo
A
A
Fracasso
C
C
Maggiorella
M T
MT
Goletti
D
D
Baroncelli
S
S
Pace
M
M
Sernicola
L
L
Koanga-Mogtomo
M L
ML
Betti
M
M
Borsetti
A
A
Belli
R
R
Akerblom
L
L
Corrias
F
F
Buttò
S
S
Heeney
J
J
Verani
P
P
Titti
F
F
Ensoli
B
B
D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology*; D000818:Animals; D000917:Antibody Formation; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D015696:Gene Products, tat / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D007111:Immunity, Cellular; D008252:Macaca fascicularis; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000628:therapy*; D015302:Simian Immunodeficiency Virus / Q000276:immunology / Q000472:pathogenicity; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014611:Vaccination; D014779:Virus Replication / Q000276:immunology; D054322:tat Gene Products, Human Immunodeficiency Virus
D016915:AIDS Vaccines; D015696:Gene Products, tat; D014409:Tumor Necrosis Factor-alpha; D054322:tat Gene Products, Human Immunodeficiency Virus